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Abstract
The widespread and often indiscriminate use of antimicrobials in animals is considered
an important driving force behind the emergence and spread of antimicrobial-resistant
bacteria. The emergence of livestock-associated methicillin-resistant Staphylococcus aureus
and the description of a novel methicillin-resistant gene, mecC, have renewed concerns
regarding the role of animals as reservoirs and a source for the evolution of novel, viru‐
lent zoonotic pathogens. The transfer of antimicrobial-resistant bacteria residing in, or on,
animals to close human contacts or the introduction of the bacteria into the food supply
chain is a cause for concern. The purpose of this mini-review is to provide a background
to the genus Staphylococcus and the emergence of antimicrobial resistance as well as a dis‐
cussion on the most significant antimicrobial resistance mechanisms. The use of antimi‐
crobials in animal husbandry is discussed and the interface between humans and
different animal populations is closely examined. Finally, the need for antimicrobial mon‐
itoring programmes is discussed and is supplemented with information pertaining to an‐
timicrobial susceptibility testing and molecular typing of staphylococcal isolates.
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1. Introduction
Staphylococci are natural residents on the skin and mucous membranes of a wide range of
host species [1]. Many of the bacterial species have a benign or symbiotic relationship with
their host; however, the bacteria may become pathogenic if they gain entry into the host tissue
through trauma of the cutaneous barrier [2, 3]. Staphylococcus aureus is the most significant
species within this genus by virtue of its versatility as a pathogen in humans and animals [4,
5]. In humans, S. aureus is responsible for a variety of conditions, ranging from superficial skin
infections to life-threatening diseases [6]. In addition, through the production of potent
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superantigens and other toxins, S. aureus can cause specific toxin-mediated conditions such as
toxic shock syndrome, scalded skin syndrome and food poisoning [6]. In animals, S. aureus is
a common cause of intramammary infections (IMIs), or mastitis [7]. Worldwide, the dairy
industry incurs significant financial losses annually due to intramammary infections [8–10].
Other Staphylococcus species, collectively termed coagulase-negative staphylococci (CNS), are
responsible for a variety of opportunistic infections in humans and animals [11]. Due to the
ubiquity of many of the species within this group, their clinical significance has traditionally
been dismissed, and when isolated from clinical specimens, the bacteria have merely been
regarded as contaminants [12]. This perception is, however, changing as many species have
emerged as important causes of nosocomial infections, particularly in relation to foreign-
device-related infections and infections in immunocompromised patients [1, 13].
The propensity for staphylococci  to develop antimicrobial  resistance is  a cause for great
concern  in  both  human  and  veterinary  medicine  [14].  As  the  efficacy  of  antimicrobials
declines, the morbidity and mortality in infected patients increase [15, 16]. Moreover, in the
case of human medicine, the costs associated with the treatment of infections caused by
antimicrobial-resistant  bacteria  represent  a  serious  public  health  burden in  hospital  and
community settings [10].
2. The genus Staphylococcus
2.1. Classification of staphylococci
Before the 1970s, S. aureus and S. epidermidis, or S. albus as it was originally named, were the
only recognized Staphylococcus species [17]. Staphylococcus aureus was considered a pathogen
and S. epidermidis, when isolated from clinical material, was regarded as a contaminant [17].
In the mid-1970s, Kloos and Schleifer [17–19] conducted comprehensive systematic studies of
staphylococci and micrococci and described a number of new species. To date, 49 species and
26 subspecies have been described and with improvements in the accuracy of genotyping
methods the number of species is still increasing [20, 21].
The genus Staphylococcus is classified along with the genera Jeotgalicoccus, Macrococcus,
Nosocomiicoccus and Salinicoccus in the family Staphylococcaceae [12, 21]. The full Linnaean
classification for the genus and the type species, S. aureus, is shown in Table 1.
In diagnostic laboratories, staphylococci are historically differentiated by their ability to
produce the enzyme coagulase, which mediates the conversion of fibrinogen to fibrin resulting
in the clotting of blood [22]. The production of coagulase has long been recognized as an
important indicator of pathogenicity [23, 24], and the coagulation of rabbit plasma provides a
rapid in vitro method for differentiating pathogenic coagulase-positive staphylococci (CPS)
and ‘non-pathogenic’ coagulase-negative staphylococci [1, 24].
Seven CPS are currently recognized, namely S. aureus, S. lutrae, S. schleiferi subsp. coagulans,
the coagulase-variable, S. hyicus and the S. intermedius group (SIG), which comprises S.
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intermedius, S. pseudintermedius and S. delphini [25, 26]. Staphylococcus aureus, which is known
to be pathogenic in both humans and animals, is considered to be the most important of all
the CPS. Other CPS, particularly S. hyicus and members of the SIG group, are important
veterinary pathogens and are responsible for infections in a number of different animal species
[2, 25, 26].
The CNS comprise a biochemically heterogeneous group of bacteria which have, for conven‐
ience, been grouped together by virtue of their inability to produce the enzyme coagulase [23,
24]. The susceptibility of CNS isolates to novobiocin has been shown to be a useful phenotypic
characteristic in diagnostic laboratories to differentiate S. saprophyticus from other clinically
important species [2, 27]. The phylogenetic relationship between the coagulase-negative
staphylococcal species has recently been clarified through the analysis of four gene loci, namely
the 16S rRNA gene and the three protein-encoding genes, dnaJ, rpoB and tuf, which code for
heat shock protein 40, the β-subunit of RNA polymerase and elongation factor Tu, respectively
[12, 28]. The molecular analysis resolved the CNS into 14 cluster groups, which are depicted
in Figure 1.
2.2. General characteristics of staphylococci
Staphylococci are non-motile, non-sporeforming Gram-positive coccus-shaped bacteria [29].
The cocci may occur singly, in pairs and in tetrads, and they characteristically divide in more
than one plane to form irregular ‘grape-like’ clusters [2, 29]. In fact, the name Staphylococcus is
derived from the Greek words ‘staphyle’ and ‘kokkos’ meaning ‘bunch of grapes’ and ‘berry’,
respectively [1, 29]. Most staphylococci are facultative anaerobes and catalase positive with
Taxonomy Name
Domain Bacteria
Kingdom Eubacteria
Phylum Firmicutes
Class Bacilli
Order Bacillales
Family Staphylococcaceae
Genus
Jeotgalicococcus
Macrococcus
Nosocomiicoccus
Salinococcus
Staphylococcus
Species Staphylococcus aureus
Subspecies Staphylococcus aureus subsp. aureusStaphylococcus aureus subsp. anaerobius
Table 1. The current Linnaean classification scheme for the genus Staphylococcus [21].
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the exception of S. aureus subsp. anaerobius and S. saccharolyticus [1]. Staphylococci can grow
in a wide pH range (4.8–9.4) and can survive temperatures of up to 60°C for 30 minutes [29].
Many Staphylococcus species are tolerant of high salt concentrations (7.5–10%) due to the
production of osmoprotectants [29]. The ability to grow in the presence of above-average salt
concentrations explains the predilection of many staphylococcal species for the sebaceous
surfaces of mammals [1]. This phenotypic trait is exploited in diagnostic laboratories by
incorporating high concentrations of sodium chloride into agar media to selectively isolate
staphylococci from contaminated samples [1, 5].
Staphylococcus aureus is able to exist as a commensal on the skin and mucous membranes of
different hosts, but when the opportunity presents, the bacterium is able to become pathogenic
[1]. Staphylococcus aureus can colonize a number of sites on the human body with the anterior
nares being the preferred site [30, 31]. Approximately 20% of healthy humans are persistent
nasal carriers of S. aureus, about 30% are intermittent carriers and around 50% of individuals
are never colonized with S. aureus [31, 32]. Individuals who are colonized by S. aureus are at a
higher risk of becoming infected and are also an important source for the dissemination of S.
aureus among individuals in the community [1, 33]. The primary means of transmission of S.
aureus is by direct contact, usually skin-to-skin contact with colonized or infected individuals,
although indirect means, via fomites, is also thought to play a role [33]. Various host factors,
including loss of the normal skin barrier, the presence of underlying diseases, such as diabetes
and acquired immunodeficiency syndrome, predispose individuals to infection [33].
Figure 1. Phylogenetic separation of staphylococcal species and subspecies. Coagulase-positive Staphylococcus spp. are
shown in green font [12, 28].
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The success of S. aureus as a pathogen is attributed in part to the capacity of the bacteria to
produce a diverse array of virulence factors [1, 14]. Some of these factors may be more
important than others in different diseases or at different stages of pathogenesis as not all
factors are produced by each strain [34, 35]. Based on structure and functionality, the virulence
factors can be broadly divided into two general groups, namely surface-associated factors and
degradative enzymes, including exotoxins [36]. The microbial surface components of S.
aureus recognizing the adhesive matrix molecular components (MSCRAMMs) comprise
surface proteins that promote colonization by binding to host cells [36]. This group, which
includes fibrinogen-, fibronetin- and collagen-binding proteins, is important during the initial
stage of infection [37]. Once infection is established, the expression of tissue-binding proteins
is downregulated, whilst the synthesis of extracellular toxins and tissue-degrading enzymes
is induced to aid the acquisition of nutrients and the dissemination of the bacteria [38].
The CNS constitute a significant proportion of the natural microflora colonizing the skin and
mucous membranes of humans and animals [12, 39]. The different staphylococcal species
display apparent site or niche preferences on their hosts and occur more frequently at these
sites [2, 12]. Staphylococcus epidermidis is the most abundant and widely distributed species on
human skin and can occur in densities of 103 to 104 cells cm−2 [12, 40, 41]. Staphylococcus
epidermidis is particularly prevalent in moist areas, such as the axillae, inguinal and perineal
areas, anterior nares, conjunctiva and toe webs [12]. Staphylococcus haemolyticus and S. homi‐
nis are preferentially isolated from areas of the skin where there are numerous apocrine glands
such as the axillae and pubic areas, whereas S. capitis is typically located around the sebaceous
glands on the forehead and scalp following puberty [2, 12]. Staphylococcus warneri is commonly
recovered from human hands, whilst S. lugdunensis has a preference for the inguinal and breast
areas [41–43].
Coagulase-negative staphylococci are typically less pathogenic than S. aureus possessing a
smaller array of virulence factors [12]. However, CNS often exhibit greater resistance to
antimicrobials and also have a greater tendency to develop multidrug resistance [44]. Coagu‐
lase-negative staphylococci are believed to serve as reservoirs of antimicrobial resistance
genes, which can transfer and integrate into the S. aureus genome leading to the emergence of
new, potentially more resistant strains [45, 46].
3. Genomic organization and genetic flexibility of S. aureus
The staphylococcal genome consists of a closed circular molecule of double-stranded DNA
between two and three megabase pairs in length and encoding between 2 509 and 2 892 open-
read frames [1, 47]. Whole genome sequencing of a number of S. aureus strains has revealed
that approximately 75% of the bacterium’s genome comprises a core component, common to
all strains [6]. The majority of the genes comprising the core genome are those associated with
central metabolism and other housekeeping functions [48]. The remaining 25% of the S.
aureus genome, termed the accessory genome, contains genes that encode a diverse array of
non-essential functions ranging from virulence, antimicrobial and metal resistance, to sub‐
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strate utilization and miscellaneous metabolism [49]. Many of the regions making up the
accessory genome are, or once were, mobile genetic elements (MGEs), such as chromosomal
cassettes, pathogenicity islands, plasmids, prophages and transposons [50]. Mobile genetic
elements can be transferred horizontally between bacteria of the same or different species,
leading to the evolution of bacterial strains [50, 51]. The distribution of these elements is
therefore important from a clinical perspective, as it may lead to the evolution of bacterial
strains that are potentially more virulent or resistant to antimicrobials [50].
3.1. Host specificity and host switching of S. aureus
Devriese and Oeding [52] were amongst the first researchers to note the occurrence of
phenotypic differences between S. aureus strains isolated from humans and different animal
hosts. A simplified biotyping scheme was developed by Devriese and co-workers to differen‐
tiate S. aureus isolates into ecological variants, or ecovars, that delineated along human, poultry
or ruminant associations [53, 54]. Many strains, however, were found not to belong to any of
the host-specific biotypes and instead were classed as non-host-specific biotypes which are
usually associated with several hosts [55]. The use of phenotyping techniques such as multi‐
locus enzyme electrophoresis (MLEE) [56] and later more discriminatory genotyping methods,
such as pulsed-field gel electrophoresis (PFGE) [55, 57], multilocus sequence typing (MLST)
[56, 58] and whole genome sequencing [59], has clearly demonstrated the existence of speci‐
alized host-specific S. aureus clones [54].
Microarray studies of animal and human S. aureus isolates have shown that strains that are
isolated from one host species tend to be uncommon in other species [60], although this
delineation is not always absolute [54]. In many respects, the host range of S. aureus should be
considered an evolving trait [61]. Adaptation to a particular host species does not prevent S.
aureus strains from causing occasional infections in other species [62]. Wherever there is an
interface between different host species, the opportunity exists for bacterial exchange. In most
cases, these exchanges lead to transient infections which are short lived due to the failure of
the S. aureus strain to establish transmission pathways in the new host species [62]. However,
sustained interspecies events are known to occur albeit at a lower frequency [62].
A number of independent studies have investigated specific S. aureus host-switching events.
All of the described host-switch events highlight the significant role that the transfer of MGEs
plays in host adaptation and specialization [56, 62, 63]. It is believed that if the conditions under
which S. aureus host switches occur is understood, then strategies could be developed to curb
future host jumps and the emergence of new human pathogens [63].
4. Staphylococcal infections in humans
Infections caused by S. aureus are often acute and pyogenic and, if left untreated, may spread
to surrounding tissue or via bacteremia to metastatic sites [2]. Some of the most common
infections caused by S. aureus involve the skin, and include furuncles or boils, cellulitis,
impetigo and post-operative wound infections of various sites [2]. Mastitis is one of a variety
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of skin and soft tissue infections that may be caused by S. aureus. Unlike other S. aureus
infections in humans, staphylococcal mastitis has not been extensively studied [60, 64]. It is
estimated that mastitis develops in approximately 1–3% of nursing mothers [65]. Infection
usually presents within two to three days after giving birth, with symptoms ranging from
cellulitis to abscess formation [65]. In severe cases, systemic symptoms such as fever and chills
may arise [65]. Staphylococcus aureus may also cause more serious infections such as bacteremia,
pneumonia, osteomyelitis, acute endocarditis, myocarditis, pericarditis, cerebritis, meningitis
and abscesses of the muscle, urogenital tract, central nervous system and various intra-
abdominal organs [2].
Staphylococcal diseases that arise exclusively from the production of staphylococcal toxins
include  staphylococcal  scalded  skin  syndrome  (SSSS),  toxic  shock  syndrome  (TSS)  and
staphylococcal  food  poisoning  [65].  Staphylococcal  food  poisoning  occurs  following  the
ingestion of food contaminated with enterotoxins [66]. Enterotoxins are heat stable and can
survive conditions that would ordinarily kill  bacteria [67].  Furthermore, enterotoxins are
tolerant to low pH conditions and the activity of proteolytic enzymes and are thus able to retain
their activity in the digestive tract following ingestion [5, 67]. Following ingestion of contami‐
nated food and a short incubation period (two to eight hours), nausea and vomiting ensue [66].
Diarrhea, hypotension and dehydration may also occur [65]. Staphylococcal food poisoning is
usually self-limiting and typically resolves within 24 to 48 hours following the onset of symptoms
[3]. Occasionally, the symptoms may be severe enough to warrant hospitalization, particular‐
ly in the case of infants, the elderly or immunocompromised individuals [66]. Staphylococcal
food poisoning is a common disease but the true incidence is considered to be underestimat‐
ed due to misdiagnosis, unreported outbreaks, improper specimen collection and laboratory
examination [66]. The disease represents a considerable burden in terms of loss of productivi‐
ty, medical and hospital expenses and financial losses to food industries [66]. Enterotoxin
production is not limited to S. aureus but has been documented in a number of other staphylo‐
cocci including S. hyicus, S. pseudintermedius, S. chromogenes, S. cohnii, S. epidermidis, S. lentus, S.
lugdunensis, S. saprophyticus, S. sciuri, S. warneri and S. xylosus [3, 5, 68, 69].
Almost half of all the CNS species that have been identified to date have been implicated in
human infections [65]. Coagulase-negative staphylococci, in particular S. epidermidis, are
frequently responsible for nosocomial infections and prosthetic-device-related infections [27,
70]. The increased infection rate is correlated with increase in the use of prosthetic and
indwelling devices in hospitals as well as the larger number of immunocompromised patients
[39, 41]. Staphylococcus epidermidis is uniquely adapted to colonize prosthetic devices by virtue
of the ability of the bacterium to produce an extracellular polysaccharide, also referred to as a
glycocalyx or slime layer, which facilitates the formation of a protective biofilm on the surface
of the implanted device [39, 65]. The process of biofilm formation and the protective effects
conferred upon the bacteria are discussed in further detail below.
Staphylococcus haemolyticus is the second most frequently encountered CNS associated with
human infections [2]. Staphylococcus haemolyticus has been implicated in native valve endocar‐
ditis, septicemia, peritonitis, urinary tract infections and wound and bone and joint infections
[2]. Staphylococcus saprophyticus is another opportunistic pathogen, which is frequently
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responsible for causing human urinary tract infections, particularly in young, sexually active
females [2, 12].
Two staphylococcal species, S. lugdunensis and S. schleferi, have been described as emerging
zoonotic pathogens [71]. Staphylococcus lugdunensis, which is known to cause skin infections
and invasive infections, such as endocarditis, osteomyelitis and sepsis in humans, has more
recently been described as an animal pathogen implicated in respiratory and skin infections
[71, 72]. Staphylococcus schleiferi, which has typically been associated with skin infections in pet
animals, has also been found associated with endocarditis and metastatic infection as well as
endophthalmitis in humans [73, 74]. Both bacterial species have been reported to cause more
serious infections than other CNS, but the exact reasons for this enhanced virulence are not
known [43, 71].
5. Staphylococcal infections in animals
Amongst all of the described staphylococcal species, only S. aureus, S. epidermidis, S. hyicus and
S. pseudintermedius are responsible for significant disease conditions in animals [75, 76]. Other
Staphylococcus spp. are predominantly associated with opportunistic infections in different
animal species [75].
In poultry, S. aureus is responsible for several infectious conditions including septic arthritis,
subdermal abscesses (‘bumblefoot’), gangrenous dermatitis and bacterial chrondronecrosis
with osteomyelitis [58, 77]. In sheep and goats, S. aureus is a common cause of dermatitis whilst
in horses and pigs S. aureus may cause botryomycosis, a chronic, suppurative granulomatous
condition [24]. In companion animals, S. aureus causes suppurative conditions similar to those
produced by S. pseudintermedius [24].
Staphylococcus hyicus is responsible for causing exudative epidermitis in pigs, also known as
greasy pig disease, as well as sporadic joint infections and cystitis [24]. In companion animals
S. pseudintermedius is commonly isolated from cases of pyoderma, otitis externa and other
suppurative conditions including mastitis, endometritis, cystitis, osteomyelitis and wound
infections [24]. Methicillin-resistant S. pseudintermedius is emerging as an important clinical
problem in veterinary medicine in many countries [78, 79].
Staphylococcus species can cause intramammary infections in a variety of animal species [24].
Bovine IMIs are the most economically significant, but in areas where sheep and goats are
maintained for milking purposes, IMIs caused by staphylococci can cause substantial losses
[80]. Similarly, in countries where milk is sourced from buffalo or camels, significant financial
losses due to mastitis have been reported [81, 82]. The direct, or obvious, financial losses
incurred as a result of IMIs include treatment costs (veterinary fees and drugs); milk that is
discarded due to poor quality, or milk lost during the required withdrawal period before and
after drug administration; increased labor costs and animal fatalities or euthanasia [83, 84]. In
addition to the direct financial losses incurred due to IMIs, a number of indirect costs exist,
which are harder to quantify and are often overlooked. Subclinical infections usually proceed
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undetected in a herd resulting in a gradual decrease in milk production and a decline in overall
milk quality [83]. This leads to a gradual erosion of profit margins, which, even when detected,
can take significant time and financial input to rectify [83].
Staphylococcus aureus is possibly the most notorious of all mastitis pathogens by virtue of the
fact that infections caused by this species are difficult to treat and tend to become chronic [36].
Coagulase-negative staphylococci are considered to be emerging pathogens, as in many
countries the CNS have become the most common bacteria isolated from intramammary
infections [9]. The species most commonly isolated from intramammary infections include S.
chromogenes, S. epidermidis, S. haemolyticus, S. simulans and S. xylosus [85, 86].
6. Antimicrobial resistance in staphylococci
Staphylococcus aureus is intrinsically susceptible to all antimicrobials that have been developed
[33]. Antimicrobial resistance may be acquired through mutation and selection of resistant
bacterial strains or through horizontal transfer of resistance genes from other bacteria of the
same or different species [33]. Common mechanisms which are used to circumvent the action
of antimicrobials include (i) the production of enzymes that inactivate or destroy the antimi‐
crobial; (ii) a reduction of the bacterial cell wall permeability limiting the antimicrobial access
into the cell; (iii) the development of alternative metabolic pathways to those inhibited by the
antimicrobial; and (iv) active elimination of the antimicrobial from the bacterial cell or the
target site [87, 88]. The mechanisms responsible for antimicrobial resistance in CNS are
identical to those occurring in S. aureus [89].
6.1. The emergence of resistance in S. aureus
Shortly after the introduction of penicillin in human medicine in 1946, reports of S. aureus
strains exhibiting resistance to this antimicrobial began emerging [90]. Penicillin-resistant
staphylococci were first recognized in hospitals and then subsequently in the community [91].
By the late 1960s, more than 80% of both community- and hospital-associated staphylococcal
isolates were resistant to penicillin [92]. It is estimated that more than 90% of staphylococcal
isolates now produce penicillinase, regardless of the clinical setting [93].
A similar clinical scenario was observed following the introduction of methicillin, the first
semisynthetic penicillin resistant to the action of penicillinase [90]. Shortly after the introduc‐
tion of methicillin in 1959, methicillin-resistant strains were reported [94]. Once again, resistant
strains initially presented in the hospital environment; and then by the late 1990s, virulent
methicillin-resistant clones emerged in the community [91].
During the 1960s, a number of non-β-lactam antibiotics, such as chloramphenicol, erythro‐
mycin,  streptomycin  and  tetracycline,  were  introduced  [89].  Although  initially  effective
against S. aureus, resistance to these antimicrobials was eventually observed [89]. By 1976,
resistance  to  gentamicin  and  kanamycin  had  been  reported,  and  by  the  early  1980s,
multidrug-resistant  S.  aureus  strains  were  reportedly  responsible  for  nosocomial  out‐
breaks in many countries [47, 95].
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Vancomycin and teicoplanin, both glycopeptide antibiotics, have been the frontline treatment
for serious methicillin-resistant Staphylococcus aureus (MRSA) infections for the last 15 years
[47, 96]. Due to the increasing burden of MRSA infections and the concomitant increase in the
usage of vancomycin, bacterial isolates showing intermediate susceptibility (not inhibited in
vitro at concentrations below 4–8 µg/ml, vancomycin-intermediate S. aureus (VISA)) were
reported in Japan in 1997 [97]. By 2002, vancomycin-resistant S. aureus (VRSA; isolates only
inhibited at antimicrobial concentrations of 16 µg/ml or more) were encountered in Michigan,
United States [33, 98].
A timeline showing the emergence of resistance in S. aureus relative to the introduction of
significant antimicrobial classes is shown in Figure 2. Several antimicrobials with good anti-
staphylococcal activity have been introduced in recent years, including ceftaroline, ceftobi‐
prole, dalbavancin, daptomycin, linezolid, telavancin and tigecycline [99, 100]. Isolates
showing reduced susceptibility to daptomycin and resistance to linezolid have already been
documented [101]. Undoubtedly, as the use of these drugs becomes more widespread, bacterial
resistance will become more common [102].
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Figure 2. The emergence of antibiotic resistance in S. aureus (VISA, vancomycin-intermediate S. aureus; VRSA, vanco‐
mycin-resistant S. aureus; CA-MRSA, community-associated methicillin-resistant S. aureus; LA-MRSA, livestock-associ‐
ated methicillin-resistant S. aureus) Adapted from [33, 47].
The distinct lack of novel antimicrobials for future use is a serious cause for concern [93, 103].
Current  strategies are aimed at  prudent and strategic  use of  antimicrobials  to delay the
emergence of resistance and ensure the longevity of antimicrobials in clinical practice [104, 105].
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6.2. Mechanism of penicillin resistance in staphylococci
Resistance to penicillin is primarily mediated by the blaZ gene, which is responsible for the
production of beta-lactamase (penicillinase), an enzyme that hydrolyzes the β-lactam ring of
the penicillin molecule [93]. The blaZ gene is part of a transposable element located on a large
plasmid, which often carries additional antimicrobial resistance genes, which confer resistance
to erythromycin, fusidic acid and gentamicin [93]. The plasmid may also carry genes encoding
resistance to disinfectants (quaternary ammonium compounds), dyes (acriflavine and
ethidium bromide) or heavy metals (cadmium, lead and mercury) [106].
6.3. Mechanism of methicillin resistance in staphylococci
Methicillin resistance arises due to the acquisition of the mecA gene, which encodes an
alternative penicillin-binding protein, PBP2a (or PBP2'), which has a low affinity for β-lactam
antibiotics [14, 100, 107]. The synthesis of PBP2a allows bacterial cell cell wall synthesis to
proceed uninterrupted in the presence of β-lactam antibiotics despite the inactivation of the
native penicillin-binding protein of the cells [93, 100]. The mecA gene confers resistance to all
β-lactam antibiotics, including cephalosporins, cefamycins and carbapenems [103, 107].
The mecA gene is part of a large mobile genetic element designated the staphylococcal cassette
chromosome mec (SCCmec) [31, 100]. The SCCmec integrates into the staphylococcal chromo‐
some of methicillin-sensitive S. aureus at a specific site (attBscc) which is located at the 3’ end
of an open reading frame of a gene with an unknown function (orfX) [33, 108]. In addition to
the mecA gene, SCCmec also carries the genes that control the transcription of the mecA gene
(mecI and mecR1) and chromosomal cassette recombinase genes (ccrA, ccrB or ccrC), which
mediate the integration and excision of the cassette into the host chromosome [31]. The
SCCmec element may also contain other genes encoding resistance to antimicrobials, such as
aminoglycosides or macrolides and resistance to heavy metal ions [109, 110]. According to
their genetic structure and contents, SCCmec elements are categorized into several types and
subtypes [14, 31]. To date, the website of the International Working Group on the Classification
of Staphylococcal Cassette Chromosome elements (IWCC) lists 11 types of SCCmec elements
(I to XI) [111].
Staphylococcal chromosomal cassettes containing the mec gene have been identified not only
in S. aureus but also in other CPS and CNS [112]. In CNS, SCCmec elements exhibit a more
polymorphous structure with a larger number of ccr–mec combinations being encountered,
which have not been described for MRSA [113]. The higher frequency and diversity of
SCCmec elements in CNS suggest that CNS are a potential reservoir of SCCmec elements, which
may facilitate and drive the emergence of new MRSA clones [114]. The possible mechanism(s)
involved in the horizontal transfer of SCCmec elements from CNS to S. aureus are currently not
known [115].
The origin of the mecA gene has been a source of speculation for many years. Homologues of
the mecA gene have been found in S. sciuri and S. vitulinus, but in both cases, the mecA gene is
not located in a mecA complex as with SCCmec [116]. Tsubakishita and co-workers [108]
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identified a mecA gene homologue in S. fleuretti, which shared almost 100% sequence homol‐
ogy with MRSA strain N315 and which resided on a structure almost identical to the mecA
complex. Staphylococcus fleuretti is a member of the S. sciuri group of staphylococci and is a
commensal bacterium of animals [108]. The occurrence of a direct precursor of the methicillin
resistance determinant in a Staphylococcus species, which normally resides on animals, suggests
that staphylococci of animal origin may be a reservoir for the evolution of novel SCCmec
elements [116].
Molecular investigations of a S. aureus isolate, which was found to be phenotypically resistant
to methicillin but negative for the mecA gene when tested with a standard diagnostic poly‐
merase chain reaction (PCR) assay, led to the discovery of a novel mecA homologue [117]. The
mecA homologue, initially designated mecALGA251 after S. aureus LGA251, the bacterial strain in
which the gene was first sequenced, shares 70% nucleotide identity with the conventional
mecA gene [118]. The work of Garcίa-Álvarez and co-workers [117] showed that mecALGA251
was found in S. aureus lineages typically associated with cattle, namely clonal complex
(CC)130, CC1943 and sequence type (ST)425, suggesting the existence of a zoonotic MRSA
reservoir. Furthermore, evidence of animal-to-human transmission of MRSA strains harboring
mecALGA251 has been documented [119]. In 2012, the IWCC renamed the mecA variant, mecC
[120]. The mecC gene resides on a novel SCCmec element designated SCCmec XI [121]. Methi‐
cillin-resistant S. aureus strains carrying the mecC gene have been shown to cause a range of
infections in humans and appear to be predominantly community associated [118, 119]. The
prevalence of mecC in CNS has not been extensively explored as yet [60], but an allotype of the
mecC gene has been detected in a S. xylosus strain [118].
6.3.1. Healthcare-associated MRSA
Traditionally, MRSA has been considered a hospital- or healthcare-associated pathogen (HA-
MRSA) primarily infecting people who are immunocompromised or who have had surgery
or medical device implants [122, 123]. Healthcare-associated MRSA strains usually carry
SCCmec types I, II and III and are multidrug resistant [14]. Worldwide, the majority of HA-
MRSA strains belong to CC5, CC8, CC22, CC30 and CC45 [14, 122].
6.3.2. Community-associated MRSA
Since the mid-1990s, MRSA strains were increasingly reported in healthy people without any
healthcare-associated risk factors [31, 122]. These cases were termed community-associated
MRSA (CA-MRSA), and genetic analyses revealed that these S. aureus isolates were genetically
distinct from the typical HA-MRSA strains [31]. Community-associated MRSA strains are
primarily associated with SCCmec types IV and V, which typically lack non-β-lactam resistance
genes [124]. Most CA-MRSA strains belong to sequence type (ST)1, ST8, ST30, ST59, ST80 and
ST93 [14, 122] with ST8 (‘USA300’) being the most common clonal lineage in the USA and ST80
the most common in Europe [125, 126]. Carriage of the gene encoding the Panton–Valentine
leukocidin appears to be epidemiologically associated with certain CA-MRSA strains [14, 123].
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6.3.3. Livestock-associated MRSA
The emergence of a third group of MRSA strains was witnessed in the last decade, which was
described following investigations that began on a pig farm in the Netherlands [54, 127]. Pig
farmers and other close human contacts were found to be at a higher risk of carrying MRSA
than members of the population who did not frequent pig farms [128]. This group of MRSA
strains, initially referred to as ‘non-typeable MRSA’ or ‘pig MRSA’, was found to belong to a
single clonal complex, CC398, with the majority of strains belonging to sequence type (ST)398
[31]. Methicillin-resistant S. aureus ST398 has subsequently been isolated from other animal
species, including dogs, horses, veal calves and poultry [125, 129–131], and it has therefore
been designated livestock-associated MRSA (LA-MRSA) [125]. It has been shown that persons
in direct (occupational) contact with LA-MRSA-positive animals, such as farmers, laborers,
veterinarians and abattoir staff, have an increased risk of becoming MRSA carriers [31].
Methicillin-resistant S. aureus ST398 strains can cause infections in both animals [31] and
humans [117]. Furthermore, certain strains belonging to an independent clade within CC398
have been associated with direct human-to-human transmission without prior exposure to
livestock [132].
Livestock-associated MRSA ST398 carries SCCmec element IV or V [133]. These strains are
generally  resistant  to  tetracycline  while  resistance  to  aminoglycosides,  lincosamides,
macrolides and trimethoprim has also been documented [31]. Fluoroquinolone resistance
has also been reported in isolates from Germany [14]. The LA-MRSA ST398 strains have
been found to carry previously unidentified resistance genes, such as dfrK, a novel, plasmid-
borne trimethoprim resistance gene [134]. This gene is located close to tetL, which would
allow for the selection of either gene by the use of tetracycline or trimethoprim, both of
which are used in veterinary medicine [135].  A novel ABC efflux pump encoding gene,
vgaC, which confers resistance to lincosamides and streptogramins, was also found on the
same plasmid [134]. The multidrug resistance gene, cfr, was found in two porcine S. aureus
isolates from Germany, one MRSA ST398 and one MSSA ST9 [136]. The cfr  gene confers
resistance  to  a  number  of  antimicrobials  including  lincosamides,  oxazolidinones,  pheni‐
cols pleuromutilins and streptogramin A [133].
Molecular typing and whole genome sequencing have revealed that LA-MRSA CC398 strains
originated from human-methicillin-sensitive S. aureus strains, which crossed the species
barrier and in the process lost phage-carrying virulence genes that are usually found in human
isolates [137]. The host switch from humans to livestock was further accompanied by the
acquisition of methicillin and tetracycline resistance genes [137], suggesting that an antibiotic
selective pressure exists in the livestock industry [138].
6.4. Mechanisms of vancomycin resistance in staphylococci
The molecular mechanisms underlying VISA and VRSA are different [139, 140]. Intermediate
vancomycin resistance is associated with the presence of a thickened and/or poorly cross-
linked peptidoglycan bacterial cell wall [140]. The altered cell wall structure traps the antimi‐
crobial molecules reducing cellular penetration and preventing the antimicrobial from
reaching its target site [140]. Heteroresistant VISA isolates (hVISA) have been described by
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Hiramatsu and co-workers [141]. Heteroresistant strains are susceptible to vancomycin but
contain a small subpopulation of cells, approximately one in every 106 cells, which exhibit
resistance. It is proposed that hVISA may be a precursor to VISA and, as such, needs to be
detected so that appropriate control measures can be implemented to limit the spread of the
bacterium [142].
Vancomycin-resistant S. aureus strains do not arise from VISA but have acquired the complete
genetic apparatus mediating resistance to glycopeptides from vancomycin-resistant entero‐
cocci [51, 93, 98]. The genes encoding vancomycin resistance, collectively referred to as the
vanA gene complex, reside on a transposon, Tn1546 [139]. The transposon is carried by a
conjugative plasmid and is transmissible to a number of Gram-positive bacterial genera
including Bacillus, Staphylococcus and Streptococcus [139].
7. Alternate bacterial strategies to circumvent the action of antimicrobials
In addition to the challenges posed by antimicrobial resistance, the treatment of staphylococcal
infections is further complicated by a number of strategies that staphylococci have developed,
which enable the bacteria to evade the host immune response and the activity of antimicrobials
[12, 143]. Two strategies, namely the formation of biofilms and the development of small-
colony variants, will be discussed in further detail.
7.1. The formation of biofilms
Biofilms can be described as large, amorphous aggregates of bacterial cells encased in extrac‐
ellular material comprising inter alia, bacterial by-products, polysaccharides and proteins [12].
Biofilms may form on abiotic surfaces, such as implanted medical devices as well as biotic
surfaces, such as host tissue [12, 39]. The formation of biofilms can be visualized as being a
four-step process: (i) the attachment of bacteria to the surface; (ii) proliferation of the bacterial
cells; (iii) biofilm growth and maturation; and finally (iv) dissociation and dissemination of
bacterial cells to new sites [12, 39].
The formation of biofilms affords bacterial cell protection from a multitude of chemical, cellular
and physical antagonists [143]. The bacteria encased in biofilms are able to tolerate significantly
higher concentrations of antimicrobials and disinfectants than free-floating bacterial cells [39,
143, 144]. Furthermore, the bacterial cells residing in biofilms are more resistant to phagocy‐
tosis and are protected from pH extremes and physical desiccation [143]. The protective effect
of biofilms is in part attributable to the physiological changes that the bacterial cells undergo
whilst growing en masse. Bacteria existing within biofilms grow more slowly than exponential-
phase bacteria [143]. This is partly due to restricted diffusion of gases and nutrients within the
biofilm environment, but this is also affected by alterations in bacterial gene expression [145].
Beenken and co-workers [145] revealed a change in the expression of 580 genes (more than
20% of the genome) when using microarrays to study differences between S. aureus cells
growing in biofilm and planktonic cultures.
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The close contact between bacterial cells residing in biofilm communities facilitates and
promotes the exchange of MGEs [146]. The horizontal transfer of plasmids in biofilms is
typically higher than observed between cells existing in a planktonic state and, in fact, studies
have shown that biofilms promote plasmid stability and may enhance the host range of MGEs
[146]. As previously discussed, the exchange of MGEs plays a significant role in the emergence
of new, potentially more virulent, staphylococcal strains.
7.2. Intracellular persistence and the formation of small-colony variants
The ability of staphylococci to persist intracellularly in non-professional phagocyctic cells
following ingestion affords protection to the bacteria from the host immune system as well as
the action of antimicrobials [12]. The adaptation to an intracellular environment is accompa‐
nied by the formation of ‘small-colony variants’ (SCVs), which represent an alternate pheno‐
typic and metabolic state of the normal, wild-type, staphylococcal phenotype [12, 147]. The
SCV phenotype is characterized by a reduced growth rate as well as substantial changes in
gene expression [12]. The altered phenotypic state also affects the susceptibility of the bacteria
to antimicrobials [144]. In addition to phagocytes, internalization of S. epidermidis in human
endothelial cells and bone cells has been demonstrated [12].
The formation of biofilms and small-colony variants is implicated in persistent and relapsing
infections, and, as such, it poses a significant challenge for the treatment staphylococcal
infections [12, 147].
8. Use of antimicrobials in animal health and food animal production
operations and implications for human health
Antimicrobials are used in animal health and food production to treat and prevent disease
and, more contentiously, for growth promotion in food production animals [148, 149]. The
volume of antimicrobials used in animals is larger than the volumes used in human medicine
even in countries where strict regulations regarding antimicrobials are enforced [148]. Exact
data on antimicrobial consumption in animals are scarce and only available for a few countries
[148]. Recent data from the USA suggest that almost 80% of antimicrobials produced are used
in food-producing animal operations [150–152] and 70% hereof are used for non-therapeutic
purposes [153, 154]. The largest users of antimicrobials are typically the poultry and swine
producers due to the intensive nature of these production systems [155].
The use and administration of antimicrobials in companion animals (cats, dogs and horses)
fall largely under the control of veterinary practitioners [148, 156]. Individual animals are
examined and diagnosed, following which the appropriate therapeutic recourse is selected
[148, 156]. In the event that antimicrobials are administered, this is done in accordance with
the manufacturer’s recommendations ensuring the prudent use of antimicrobials [148]. In
contrast, the use of antimicrobials in food production animals (livestock and poultry) is often
done with little or no veterinary consultation [148]. Many antimicrobials are accessible to
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producers as ‘over-the-counter’ remedies from local retailers, thereby limiting the control over
the use of these products [148, 157]. In food production animals, antimicrobials may be applied
therapeutically to treat sick individuals, but it is more common for producers to apply
antimicrobials to entire herds or flocks in order to treat sick animals and to curb the spread of
infectious organisms to healthy animals [148, 156]. The administration of antimicrobials in this
manner is termed metaphylaxis [148, 158].
In food production systems, antimicrobials are often intentionally administered to animals in
sub-therapeutic doses to promote growth and enhance feed efficiency [148]. The benefits of
using antimicrobials as ‘growth promoters’ were recognized as early as the 1940s [149, 158].
Researchers observed that poultry that were administered vitamin B12 in the form of crude
Streptococcus aureofaciens fermentations showed improved growth compared to birds given
purified vitamin B12 [159]. It was speculated that the crude fermentations contained an
unidentified growth factor, which enhanced growth [158]. The growth factor in the fermenta‐
tion product was subsequently identified as chlortetracycline [158]. Shortly after this obser‐
vation, the US Food and Drug Administration (FDA) approved the inclusion of certain
antimicrobials into animal feed to enhance animal growth and production as well as prevent
disease [158]. Some of the antimicrobials which have been utilized as growth promoters in
some countries include: avilamycin (everninomycin), avoparcin (glycopeptide), bacitracin
(polypeptide), bambermycin (glycolipid), carbadox and olaquindox (quinoxalines), lincomy‐
cin (lincosamides), pencillin (β-lactams), streptomycin (aminoglycosides), tetracycline and
chlortetracycline (tetracyclines), tylosin and spiramycin (macrolides) and virginiamycin
(streptogramin) [156, 159, 160].
The use of antimicrobials in animals, particularly as growth promoters in food producing
animals, has been subjected to intense scrutiny and is frequently criticized as a driving force
behind the emergence, maintenance and horizontal transfer of antimicrobial-resistant deter‐
minants in bacteria [161, 162]. The principle concern is the potential zoonotic transmission of
antimicrobial-resistant pathogenic and non-pathogenic bacteria to humans either through
direct contact with animals or indirectly through contact with the animals’ environment or
through the food chain [161, 163]. Due to public concerns and increasing scientific evidence,
stricter regulations regarding the use of growth promoters have been implemented [164]. The
European Union began phasing out the use of antimicrobials for growth promotion in the late
1990s [163]. By the year 2000, Denmark had successfully implemented a complete ban of
antimicrobial growth promoters in food animal production [157, 160]. Stakeholders in favor
of restrictions have argued that in countries like Denmark, where bans have been introduced,
there has been a concomitant decrease in antimicrobial resistance in animal and human
bacterial isolates [164]. Opponents to the ban of growth promoters have, however, questioned
the evidence provided by supporters of the ban and have argued that a decline in the use of
growth promoters will negatively affect productivity and animal health, which will in turn
lead to an increase in the therapeutic use of antimicrobials [149, 164]. A number of excellent
reviews have examined the complexity and debate surrounding the use of growth promoters
in livestock production, and the reader is referred to these texts for further information [148,
149, 157, 165–167].
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9. The interface between human and animal populations
The dynamics of staphylococcal antimicrobial resistance and bacterial transmission at the
human–animal interface will be considered separately for companion animals (cats, dogs and
horses) and food production animals (livestock and poultry). Consideration will also be given
to the intersection of humans and animal carcasses further along the food chain in the abattoir.
9.1. Companion animals
It is common in developed countries for humans to own companion animals [126]. Due to the
close contact between humans and their pets, the opportunity for the transmission of bacteria
between hosts is high [126]. Numerous reports have documented the transmission of MRSA
strains between humans and dogs [168–174], humans and cats [175, 176] and humans and
horses [177, 178]. Bacterial transmission of MRSA leads to both hosts becoming colonized,
which places the hosts at a higher risk of being infected by the colonizing strain when the
opportunity presents [78]. Furthermore, the colonized hosts serve as reservoirs of MRSA for
other members of the household [179, 180].
Molecular genotyping of MRSA isolates recovered from companion animals has revealed that
the S. aureus strains recovered from colonized and infected animals usually belong to clonal
complexes implicated in human infections [126, 171, 173, 174, 177, 181, 182]. An investigation
conducted in the United Kingdom examined the occurrence and the genetic relatedness of
MRSA recovered from veterinary personnel and hospitalized animals in a small animal
hospital [171]. Eighty-two percent (23/28) of the MRSA isolates recovered from the nasal
mucosa of staff, hospitalized dogs and the environment were genetically related to EMRSA-15
(ST22), the predominant MRSA clone responsible for nosocomial infections in the United
Kingdom [171]. In the USA, the most common MRSA clone recovered from companion animals
is the ST5 clone, which is also the most common HA-MRSA clone in humans [171]. These data
have suggested that the transmission of MRSA usually occurs from the human host to their
respective pet [78, 179].
In general, prevalence studies seem to suggest that MRSA colonization amongst healthy pets
is low [126, 176]. Higher MRSA colonization rates have been documented amongst companion
animals in settings like animal shelters and veterinary hospitals [126, 171, 183]. Presumably,
due to the relatively low MRSA colonization of companion animals there is currently no
significant evidence indicating that pet owners are at an increased risk of MRSA colonization
or infection compared with humans who do not own pets [107]. However, it is suggested that
the lack of evidence may be partly attributed to the paucity of studies examining this particular
aspect of animal ownership [107].
Since 2006, there has been a significant increase in the number of documented cases involving
the isolation of methicillin-resistant S. pseudintermedius (MRSP) strains from surgical wound
infections of dogs and cats [79]. A few studies have reported the occurrence of indistinguish‐
able strains of MRSP from humans and their canine companions [176] and amongst animals
and workers in veterinary clinics [184]. In Japan, a study investigating the prevalence of MRSP
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in a veterinary teaching hospital, cultured MRSP from 17 dogs and a staff member [25]. The
isolate recovered from the employee had an antimicrobial susceptibility pattern and a PFGE
profile similar to isolates recovered from dogs handled at the facility, indicating zoonotic
transmission [25]. A study investigating the prevalence of MRSP in staff working at a veteri‐
nary dermatology practice reported that 5.3% (9/171) of the staff tested positive [185]. In
general, owners of infected pets and veterinarians handling infected animals seem to have a
higher risk of being MRSP positive [79]. In all documented cases, MRSP-positive individuals
have been asymptomatic [79].
9.2. Food production animals
Livestock and poultry production has, over the past few decades, intensified in order to keep
abreast with the food demands posed by a burgeoning human population [138, 148]. Larger
numbers of animals are maintained under confined conditions in order to maximize produc‐
tivity and improve profit margins. Accompanying these changes in farming practices has been
an increase in the use of antimicrobials as well as increase in the proximity in which animals
and humans co-exist [137, 138]. The close proximity of animal and human hosts has in turn
increased opportunities for the transmission and exchange of microbial flora [56, 138]. It is well
established that individuals such as farmers, veterinarians, farm laborers and abattoir workers
working in close contact with animals have a greater risk of being colonized or even infected
with zoonotic bacteria carried by animals than individuals that do not interact with animals
[31]. The relatively recent description of zoonotic LA-MRSA ST398 and the novel methicillin
resistance gene, mecC, has once again highlighted the implications associated with the
horizontal transmission of pathogenic bacteria between animal and human hosts and the role
of animals in the epidemiology and the evolution of human disease [118, 186].
Since the description of LA-MRSA, a plethora of studies have been conducted to estimate the
prevalence of MRSA in different food animals, and a number of reviews have been published
[14, 31, 107, 125]. Livestock-associated MRSA has been extensively described in pig production
systems with many investigations documenting the transmission of CC398 between animals
and close human contacts [187–193]. A study conducted in Germany found 86% (97/113) of
people who worked with pigs to be asymptomatic carriers of CC398 MRSA [190]. Interestingly,
in the same study, sampling of the family members of CC398 MRSA carriers showed that 4.3%
(5/116) of these individuals, who had no direct exposure to pigs, were colonized by the same
MRSA strain [190]. Nasal colonization was also found in 45% (22/49) of veterinarians fre‐
quenting pig farms in the study area and in 9% (4/44) of their family members who had not
been exposed to pigs [190]. A pilot study conducted in two large pig production systems in
the USA revealed an overall MRSA prevalence of 49% (147/299) in the animals sampled and
45% (9/20) of the farm workers [194]. All MRSA isolates belonged to ST398 [194]. In Belgium,
37.8% (48/129) of close human contacts sampled from 50 pig farms were found to be colonized
by MRSA ST398 [191]. An identical MRSA strain was recovered from the skin lesions of one
worker who was sampled at the time of the study [191]. In some geographical settings, other
MRSA clones have been found to colonize pigs. In China, MRSA strains belonging to ST9 were
commonly isolated from pigs and close human contacts [195, 196]. In Italy, pigs sampled at
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abattoirs were found to be colonized by MRSA ST9, ST(CC)97 and ST398 [197]. Further, the
presence of human-associated CA-MRSA t127, ST1 and SCCmec type V was detected [197].
Despite the high rate of LA-MRSA colonization in pigs, this S. aureus clone has only been
implicated in sporadic clinical infections in pigs [107]. Livestock-associated MRSA has been
isolated from skin infections such as exudative epidermidis and infections of the urogenital
tract and the uterus and mammary gland of pigs [14].
In the Netherlands, MRSA ST398 colonization has been documented in veal calves and close
human contacts [131]. From the 102 farms sampled in one study, MRSA was isolated from
animals on 88% (90/102) of the farms investigated [131]. Overall, 28% (602/2151) of the animals
and 33% (32/97) of the farmers sampled tested positive for MRSA [131]. The MRSA strains
recovered from the human and animal samples included ST398 as well as ST5, ST15, ST45 and
CC34 from the human specimens and ST97, ST239, ST1159 and CC425 from the calves [131].
The data clearly demonstrated that MRSA colonization of human contacts was strongly
associated with the intensity of animal contact and with the number of MRSA-positive animals
on the farm [131]. Furthermore, a direct correlation was observed between MRSA prevalence
and farm hygiene practices [131].
In dairy cattle operations, LA-MRSA ST398 has been isolated from clinical and subclinical
milk samples. One of the first reports, emanating from Belgium, recovered LA-MRSA from
9.3% (11/118) of the dairy farms surveyed [198]. The prevalence on positive farms varied
between 3.9% and 7.4% [198]. Methicillin-resistant S. aureus ST398 has also been reported
from dairy herds in Germany [199] and Switzerland [61, 200]. Juhász-Kaszanyitzky and co-
workers [201] published the first report documenting the transmission of MRSA between
dairy cows with mastitis and a close contact worker on the farm. In this study, identical
MRSA strains, belonging to MLST ST1, were recovered from both animal and human hosts.
The direction of transmission, from bovine to human or human to bovine could, howev‐
er, not be established [201].
One of the first reports of LA-MRSA in poultry emerged following a study conducted in
Belgium [130].  The researchers  reported that  12% (10/81)  of  the S.  aureus  isolates  recov‐
ered from the nasal and cloacal swabs of healthy broiler chickens belonged to spa  types
associated with CC398 [130]. A further study in Belgium identified a new spa type, t1456,
within CC398 following a random sampling of broiler farms [202]. Despite sporadic reports
on the isolation of CC398 from poultry operations, the epidemiology of LA-MRSA in poultry
is still unclear [14].
According to Schwabe [203], a zoonosis is described as a ‘shared infection’ of animals and
man, without ascribing direction of transmission from one host to the other. Inasmuch as
bacterial  transfer  and colonization,  or  infection,  of  humans are  of  significant  concern to
human medicine, the reverse scenario, which is often overlooked, warrants consideration.
Humans  may  represent  an  important  source  of  new  bacterial  strains,  which  can  cause
disease  in  livestock and,  as  such,  pose  a  potential  threat  to  food security  [138].  Several
molecular genotyping studies, which have traced the origins of epidemic S. aureus clones
in human and animal hosts,  have reported that  the majority of  host-switch events have
involved the movement and adaptation of bacteria from human to animal hosts [62]. Both
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LA-MRSA ST398 and the major pathogenic S. aureus  ST5 clone, responsible for lameness
in  poultry,  have  been  shown  to  originate  from  humans  but  have  now  adapted  and
diversified to spread in animal hosts [58, 137].
Irrespective of the direction of bacterial transmission, it is of mutual benefit to both human
and animal health that bacterial populations at the interface between different host species are
monitored. Surveillance is therefore advocated in order to monitor changes in the epidemiol‐
ogy and virulence of bacterial strains and to enable appropriate pre-emptive measures to be
taken [138].
9.3. Food animal products
The abattoir environment presents a dynamic interface between humans and animals largely
due to the fact that abattoirs process large numbers of animals originating from different farms
across a relatively broad geographic expanse. During slaughtering and subsequent processing,
it is quite plausible for carcasses to become contaminated with staphylococcal strains origi‐
nating from animals, abattoir workers or the environment [14]. Numerous reports have
documented the occurrence of CA-MRSA, HA-MRSA and LA-MRSA strains from different
meat products [14, 204, 205, 206]. An extensive study conducted in the Netherlands demon‐
strated the presence of LA-MRSA on a variety of raw meat products collected from retail outlets
[204]. In this study, 11.9% (264/2217) of the raw meat products analyzed were found to be
positive for MRSA [204]. It was further shown that 85% (224/264) of the MRSA strains belonged
to spa types associated with CC398 [204]. A survey conducted in the USA found 39.2% (47/120)
of the retail meat samples analyzed to be positive for S. aureus. Five percent (6/120) of the S.
aureus isolates were resistant to methicillin. Molecular typing identified the isolates as
belonging to the ST5 and ST8 lineages [205]. A similar survey conducted in Canada found 7.7%
(31/402) of the meat samples analyzed contained MRSA [206, 207]. The three major sequence
types obtained were ST5 (29%), ST8 (39%) and ST398 (32%) [206, 207].
The principal concern arising from the presence of MRSA in food is the development of food
poisoning following ingestion of preformed staphylococcal enterotoxins [207]. The best
preventative measure is to ensure the correct handling and storage of food to reduce the risk
of enterotoxins being produced [207]. Another concern regarding the presence of MRSA on
meat is that people may become colonized or infected from handling or eating contaminated
meat [205, 207]. Regarding the latter, there is, at present, no substantial data to support or refute
this concern. More intensive surveillance is needed to elucidate the true role of food contam‐
ination in the development of human diseases [107].
10. Monitoring antimicrobial resistance in staphylococci at the human–
animal interface
In addition to direct contact between animal and human hosts, the transmission of antimicro‐
bial-resistant bacteria and resistance genes may occur through a number of routes [76, 149].
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Figure 3 presents some of the potential routes of bacterial transmission taking into consider‐
ation the role of the environment as well as aspects related to the movement of animals, food
products and human contacts. The globalized trade of live animals and/or meat products is
one of the features of modern food production systems, which has the potential to elaborate
the impact of antimicrobial-resistant bacteria of animal origin [138].
Figure 3. Potential routes of dissemination of antimicrobial-resistant bacteria and antimicrobial resistance genes [76,
149]. ©2005 American Society for Microbiology. Adapted with permission. No further reproduction or distribution is
permitted without the prior written permission of American Society for Microbiology
In order to be able to accurately assess the impact of antimicrobial use in animal health and
food production operations on human medicine, integrated surveillance programmes are
needed [148]. The formulation and implementation of surveillance programmes require a
concerted effort from role-players in multiple disciplines. Funding, infrastructure, political
‘buy-in’ and the support of several role-players are key to the success of these programs [148].
Currently, only a few countries have been able to implement successful monitoring pro‐
grammes [148]. One of the longest running and most successful programmes is the Danish
Integrated Antimicrobial Resistance Monitoring and Research Programme (DANMAP), which
has been systematically collecting and analyzing data since 1995 [163]. The programme utilizes
a ‘one-health’ approach and entails the monitoring of the entire food chain from ‘farm to fork
to sickbed’ [208]. The objectives of DANMAP are summarized as follows:
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• to monitor the use of antimicrobial agents in food animals and humans;
• to monitor the occurrence of antimicrobial resistance in bacteria isolated from food animals,
food of animal origin and humans;
• to study associations between antimicrobial consumption and antimicrobial resistance; and
• to identify routes of transmission of resistant bacteria and/or resistance determinants and
areas for further research [163, 208].
Results from DANMAP are reported annually and are accessible online [163]. The data
accumulated from long-term surveillance programmes should enable resistance trends to be
monitored over periods of time as well as identify emerging problems so that adequate
intervention strategies can be implemented [148, 208].
In accordance with Office International des Epizooties (OIE) guidelines, surveillance pro‐
grammes should investigate antimicrobial resistance in the following groups of bacteria:
1. Human and animal pathogens that cause infections. These bacteria are thought to reflect
resistance caused by the use of antimicrobials in the respective reservoirs.
2. Zoonotic bacteria that can develop resistance in the animal reservoir and which can be
transmitted to humans via direct contact or consumption of contaminated food. These
bacteria may subsequently compromise treatment when causing infection in humans.
3. Sentinel or indicator bacteria, such as enterococci and Escherichia coli, are selected for
monitoring purposes due to their ubiquity in animals, foods and humans. Furthermore,
these bacteria readily develop or transfer antimicrobial resistance in response to selective
pressure in both human and animals and are considered reservoirs of resistance deter‐
minants [148, 208, 209].
The staphylococci of animal origin which are commonly monitored as part of surveillance
programmes include S. aureus and coagulase-negative staphylococci from bovine mastitis
cases as well as S. hyicus isolates from cases of exudative epidermitis in pigs [148, 163]. From
human health laboratories, S. aureus isolates derived from blood, urine and CSF samples are
used for surveillance purposes [208, 209]. Some surveillance programmes, such as the British
Society for Antimicrobial Chemotherapy Resistance Surveillance project, extend monitoring
to include CNS species [209].
11. Evaluating the antimicrobial susceptibility of staphylococcal isolates
In a clinical context, evaluating the antimicrobial susceptibility of bacterial isolates is an
important aid for practitioners needing to make decisions regarding the appropriate thera‐
peutic treatment of infected patients [88]. Antimicrobial susceptibility testing of bacterial
isolates also provides essential data for surveillance programs as previously discussed. Several
methodologies exist for evaluating the in vitro susceptibility of bacterial isolates to different
classes of antimicrobials. The two principal methods used are agar disk diffusion and the broth
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micro-dilution minimum inhibitory concentration (MIC) method [148, 210]. The agar disk
diffusion method provides qualitative results that categorize isolates as susceptible, inter‐
mediate or resistant to the antimicrobial(s) under evaluation [135, 210]. The method is
relatively cost-effective and flexible with respect to the panel of antimicrobials that can be
selected for testing [135]. The MIC method may be performed in a variety of formats ranging
from in-house prepared plates or broths to commercially available micro-dilution plates or
gradient strips [210]. The MIC method provides a quantitative result expressed in micrograms
per milliliter as well as a categorization of the bacterium as susceptible or resistant [135, 210].
Since the method is able to quantify antimicrobial susceptibility, the MIC is the preferred
method for use in surveillance or epidemiological programs [148].
Irrespective of the test methodology selected, it is imperative that all antimicrobial suscepti‐
bility tests are conducted in accordance with the international standard being followed, namely
the Clinical Laboratory Standards Institute (CLSI), the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) or other recognized national standards [210]. Furthermore,
it should be ensured that all of the appropriate quality control measures advocated by the
standard are implemented and rigorously followed [210].
In vitro methods for analyzing the antimicrobial susceptibility do not take into consideration
the protective effect afforded by biofilm growth, which commonly occurs during the course
of staphylococcal infections [143]. Due to the protective environment afforded by biofilm
growth and the accompanying changes in bacterial physiology, bacterial cells growing in
biofilms are typically able to tolerate antimicrobial concentrations 10-fold to 1000-fold higher
than planktonic bacterial populations [143]. A few methods have evolved to investigate the
antimicrobial susceptibility of isolates growing in biofilms, with the commercially available
method from Innovotech Inc. (Edmonton, Canada) gaining wide acceptance. The Innovotech
MBECTM P&G system is a uniquely designed microtiter plate with 96 identical pegs protruding
from the plastic lid (Innovotech Inc., 2012). The system facilitates the generation of 96 identical
biofilms on the pegs which can be subjected to varying concentrations of antimicrobial or
disinfectant to calculate the minimum biofilm eradication concentration (MBEC) and MIC
values for each test isolate (Innovotech Inc., 2012). The Innovotech MBECTM P&G system
(formerly called the Calgary biofilm device) has been used in a number of applications to
examine the effect of different chemicals on staphylococcal biofilms [211–215].
11.1. Detection of antimicrobial resistance genes in staphylococcal isolates
A complementary approach to phenotypically evaluating the susceptibility of staphylococcal
isolates is to screen test isolates for specific antimicrobial resistance genes using molecular
assays, such as PCR and real-time PCR [24, 216]. This approach is still only infrequently used
in routine clinical diagnostic work, but from a research perspective, molecular screening has
provided a wealth of information with respect to the distribution and spread of resistance
genes amongst bacteria [88].
An obstacle to using DNA-based assays for resistance testing is the formidable complexity of
resistance mechanisms that exist [217]. It is common for resistance to an antimicrobial to
involve multiple genes and, in some cases, not all of the mechanisms involved have been
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identified [217]. The use of microarrays is one manner in which this limitation has been
overcome [216]. Microarray analysis enables bacterial isolates to be simultaneously screened
for a large number of gene targets [216]. A DNA microarray consists of an orderly arrangement
of DNA probes which have been spotted onto a solid support, such as a silicon chip, glass slide
or nylon membrane [216]. Bacterial DNA or cDNA is labelled with a fluorescent dye and
allowed to hybridize to the microarray [216]. One of the microarrays currently available
commercially, the StaphyType Kit (Alere Technologies, Jena, Germany) permits the simulta‐
neous screening of 334 S. aureus gene targets. In addition to screening for a multitude of
antimicrobial resistance genes, the kit screens bacterial isolates for species-specific gene
markers, toxin-encoding genes and genes encoding specific tissue-binding proteins [218].
12. Epidemiological molecular typing systems for staphylococci
Bacterial typing is important for both clinical and epidemiological investigations to determine
the source(s) of infection, routes of transmission in disease outbreaks or the analysis of the
genetic relatedness or specific characteristics of bacterial strains [219]. A number of different
typing techniques have been developed, each with specific advantages and drawbacks. It is
therefore imperative that the most appropriate method, or combination of methods, be selected
depending on the purpose of the investigation on hand [219].
Pulsed-field gel electrophoresis is a highly discriminatory technique and is considered to be
the ‘gold standard’ for typing S. aureus isolates of both human and animal origin [14]. Pulsed-
field gel electrophoresis is also the recommended strain typing technique for S. epidermidis and
other CNS [220]. Pulsed-field gel electrophoresis detects rapidly accumulating genetic
variation and is therefore useful for distinguishing strains for the investigation of an outbreak
or for examining the phylogeny of a small bacterial population [60]. The PFGE technique is
based on the digestion of bacterial DNA with restriction enzymes that cleave specific recog‐
nition sites along the chromosome [221]. The restriction enzyme digestion generates a number
of DNA fragments, which are resolved by electrophoresis in an electric field, which is pulsed
at different angles across the gel. The resulting banding patterns are analyzed using specific
software and interpretations made according to the criteria of Tenover and co-workers [222].
The principal drawbacks of this technique are the fact that this method is technically demand‐
ing and time consuming and requires several days before results are available [223]. Further‐
more, specialized equipment is required to perform the gel electrophoresis [122, 223]. Inter-
laboratory reproducibility of results has also been problematic, making the comparison of data
generated by different laboratories quite difficult [122].
Multilocus sequence typing (MLST) is a sequence-based genotyping method, which is
performed by sequence analysis of approximately 450-bp internal fragments of seven house‐
keeping genes [224]. The DNA sequences for each locus are assigned distinct allele identifica‐
tion numbers, and the combination of the numbers defined for all loci is used to generate the
sequence type (ST) [33, 122]. Isolates that have identical sequences at all seven loci are
considered a clone, whereas sequence types that differ by single nucleotide polymorphisms
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at fewer than three loci are considered closely related and are grouped in clonal complexes
(CC) [14, 33]. In contrast to PFGE, MLST indexes genetic variations that accumulate slowly
over time [125]. Multilocus sequence typing is, therefore, better suited to measure evolutionary
changes over a relatively long time span and is the best method for studying the global
epidemiology and frequency of specific bacterial lineages [60, 125]. The method is highly
discriminatory and has the distinct advantage of enabling results from other laboratories and
studies to be compared using the Internet [122, 224]. At present, the greatest limitation to using
MLST is the high cost associated with the sequencing of multiple gene loci [125].
Typing of the spa gene is also widely used for the epidemiological study of S. aureus isolates
[1]. The spa gene encodes protein A, an important virulence factor of S. aureus [225]. The typing
method entails the DNA amplification and sequencing of a polymorphic 24-bp variable-
number tandem repeat (VNTR) within the coding region of the spa gene followed by the
assessment of the data using a central online server. Typing of the spa gene has been found to
be a suitable typing method for conducting both local and global epidemiological studies [226].
This method has been found to have a greater discriminatory power than MLST but it is less
discriminatory than PFGE [122, 227, 228]. Since spa typing involves the sequencing of only a
single locus compared with MLST, it is cheaper, less laborious and less time consuming to
perform [125, 228]. A potential problem, however, is that unrelated lineages can sometimes
contain similar spa types [125].
Typing of the SCCmec element is one of the most important epidemiological tools for studying
methicillin-resistant staphylococci [228]. A number of multiplex PCR and real-time PCR assays
have been developed to classify the different SCCmec types and subtypes [229–234]. An
overview of the scope and drawback of various SCCmec typing methods, which have been
developed, can be found elsewhere [91]. At present, there is no universally accepted assay
which can identify and differentiate all of the mec types and subtypes [122]. Furthermore, since
the described PCR assays target different regions of the SCCmec element, it is not uncommon
for discrepant results to be obtained when different methods are used to test the same isolates
[228].
13. Concluding remarks
Staphylococci are ubiquitous in the environment and occur commensally on the skin and
mucous membranes of humans and animal hosts. The genetic flexibility of bacteria in this
genus, particular S. aureus, is the primary evolutionary driving force behind the emergence of
new strains exhibiting enhanced virulence and antimicrobial resistance. The use of antimicro‐
bials in animal health and food animal production operations has been implicated as a driving
force behind the development of antimicrobial-resistant bacteria, which can transfer to humans
through direct contact or indirectly through the food chain or environment. However, much
of the evidence put forward to corroborate the argument against the use of antimicrobials in
food animal production operations is tenuous and, if anything, it supports the need for further
surveillance data. The implementation and maintenance of national and international inte‐
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grated antimicrobial resistance surveillance systems are required. Through active monitoring,
potential problems can be identified and appropriate guidelines and policies put in place to
ensure the longevity of clinically important antimicrobials.
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